New pharmaceutical products face many potential hurdles to commercial success including regulatory approval, national and regional market access, and physician and patient acceptance and uptake, to name a few. Each stage of the development cycle involves an ever-widening group of stakeholders. Securing the buy-in of these influential external stakeholders requires pharmaceutical companies to look inward and encourage cross-functional collaboration and the ability to engage early, and often, along the path to launch and beyond. To read more, click the link below.
ESMO 2024 review: Improving patient survival through innovations in oncology
European Society for Medical Oncology (ESMO) Congress 2024 was held in Barcelona, Spain, bringing together the global oncology community to share the latest...